Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 17, 2026.

TNF-α and neuropathic pain - a review

Lawrence Leung, Catherine M Cahill

Journal of Neuroinflammation · 2010 · Review

doi:10.1186/1742-2094-7-27

Abstract

Tumor necrosis factor alpha (TNF-alpha) was discovered more than a century ago, and its known roles have extended from within the immune system to include a neuro-inflammatory domain in the nervous system. Neuropathic pain is a recognized type of pathological pain where nociceptive responses persist beyond the resolution of damage to the nerve or its surrounding tissue. Very often, neuropathic pain is disproportionately enhanced in intensity (hyperalgesia) or altered in modality (hyperpathia or allodynia) in relation to the stimuli. At time of this writing, there is as yet no common consensus about the etiology of neuropathic pain - possible mechanisms can be categorized into peripheral sensitization and central sensitization of the nervous system in response to the nociceptive stimuli. Animal models of neuropathic pain based on various types of nerve injuries (peripheral versus spinal nerve, ligation versus chronic constrictive injury) have persistently implicated a pivotal role for TNF-alpha at both peripheral and central levels of sensitization. Despite a lack of success in clinical trials of anti-TNF-alpha therapy in alleviating the sciatic type of neuropathic pain, the intricate link of TNF-alpha with other neuro-inflammatory signaling systems (e.g., chemokines and p38 MAPK) has indeed inspired a systems approach perspective for future drug development in treating neuropathic pain.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 17, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Despite intense research over the last 30 years, debate is still ongoing regarding the nature of neuropathic pain, including controversy as to whether such pain is peripheral or central in origin, and as to whether its etiology is inflammatory or non-inflammatory. Increasing evidence has provided better understanding of the roles of both immune and pro-inflammatory mediators (e.g., the interleukins, TNF-α, complement components, ATP and the chemokines) in the mechanisms of both peripheral and central neuropathic pain. This review will concentrate on current knowledge and experimental models regarding the role of TNF-α, among other cytokines, in neuropathic pain; with an appraisal of available potential therapeutic targets related to TNF-α and directions for future developments in this area.

Neuropathic pain as an example of an inflammatory pain model

Neuropathic pain is characterized by disproportionate hypersensitivity to stimuli (hyperalgesia), abnormal pins-and-needles or electric-shock-like sensations (hyperpathia) and, finally, nociceptive responses to non-noxious stimuli (allodynia). It is a pathological type of pain that persists despite resolution of the inciting damage to the nerve and the surrounding tissues. From a behavioral standpoint, nociception is an adaptive tool for better survival, while neuropathic pain is considered maladaptive. The prevalence of neuropathic pain ranges from 1% in UK to 1.5% in the US to 17.9% in Canada. Weir Mitchell is often credited with the first descriptive account of neuropathic pain from nerve injuries seen in the US Civil War, using terms that range from "burning", "mustard red hot", "red-hot file rasping the skin" to "with intensity ranging from most trivial burning to a state of torture". Clinically, the top three most common types of neuropathic pain are post-herpetic neuralgia, trigeminal neuralgia and diabetic neuropathy. Neuropathic pain is among the most difficult types of chronic pain to treat, which not only significantly impairs patients' quality of life but also adds to the burden of direct and indirect medical cost for our society. Conceptually, neuropathic pain consequent to peripheral nerve injury results from an increased excitability of the neurons as a result of sensitization. The debate is still on-going as to whether this sensitization occurs in the peripheral or central compartments of the nervous system, or both. Experimentally, various animal models of peripheral neuropathic pain have been developed: chronic constriction injury (CCI) of the sciatic nerve with loose ligatures; partial sciatic nerve injury with tight ligatures; total sciatic nerve ligation; sciatic nerve transaction and axotomy of lumbar roots entering the sciatic nerve. Despite the various degrees and modes of nerve damage in these models, there is a common sequel--post-injury inflammatory changes leading to mast cell degranulation, and recruitment of both macrophages and polymorphonuclear neutrophils. However, in CCI models thermal hyperalgesia still occurs when ligatures are loosely placed around the sciatic nerve without actual mechanical damage. This finding supports the hypothesis that it is the inflammatory microenvironment and the release of mediators, rather than the nerve injury per se, that is pivotal for the development of neuropathic pain. Clatworthy et al. further demonstrated that suppression of the inflammatory response with dexamethasone reduces thermal hyperalgesia, while enhancing the inflammatory response using Freud's adjuvant was seen to aggravate the level of pain hypersensitivity. His work set the stage for continuing research on immune and pro-inflammatory mediators in neuropathic pain over the next two decades. An updated list of such mediators, by no means exhaustive, includes the eicosanoids, bradykinins, serotonin, ATP/ADP, neurotrophins, cytokines, chemokines, and reactive oxygen species. These mediators are not exclusive to cells of immune/inflammatory origin, but are also produced by Schwann cells and spinal glial cells, thereby potentially mediating the mechanisms of neuropathic pain.

Cytokines in neuropathic pain

Cytokines are low molecular weight glycoproteins that are secreted mainly, but not exclusively, by immunological cells such as T-cells, macrophages and neutrophils. Other cells that secrete cytokines include keratinocytes and dendritic cells of the skin and Schwann cells and glial cells of the central nervous system. They act as intercellular mediators regulating the functions and differentiation of neighboring cells and are produced in response to disease, inflammation, or tissue damage. Cytokine synthesis is prompt and their actions are often localized with a relatively short half-life. This distinguishes them from hormones which are constantly produced with longer-lasting and more distant effects. The first cytokine was discovered by Beeson in 1948 as a pyrogenic compound extracted from ploymorphonuclear leucocytes, later known as IL-1β. Since then, many other cytokines have been discovered, and these fall into five main categories: interleukins, interferons, tumor necrosis factors, growth factors and chemokines. Together, these factors contribute to the pathogenesis of neuropathic pain. In particular, tumor necrosis factor alpha (TNF-α), interleukin-1 (IL-1) and interleukin-6 (IL-6) have been associated with the development of neuropathic pain in various animal models. In this review, we shall limit our scope to TNF-α.

Tumor necrosis factor alpha (TNF-α): a neuropathic pain-related cytokine

In 1891, the success story of William Coley in using supernatant extract of heat-killed mixtures of Streptococcus pyogenes and Serratia marcescens bacteria to treat tumors may in fact be the first discovery of tumor necrosis factor. It was not until 1975 that an endotoxin-like substance was described in activated macrophages with tumor-regression activity and was given the name of tumor necrosis factor alpha, TNF-α. TNF-α belongs to a superfamily of ligand/receptor proteins called the tumor necrosis factor/tumor necrosis factor receptor superfamily proteins (TNF/TNFR SFP). TNF-α possess a trimeric symmetry with a structural motif called the TNF homology domain (THD), which is shared with all other members of the TNF proteins. This THD binds to the cysteine-rich domains (CRDs) of the TNF receptors (TNFRs), and variations of these CRDs lead to heterogeneity of the TNFRs. TNFRs are either constitutively expressed (TNFR1, p55-R) or inducible (TNFR2, p75-R). In the context of neuropathic pain, using the standard model of chronic constriction injury (CCI) of sciatic nerve in rats, TNF-α has been detected at the injury site and shows temporal up-regulation; here TNF-α is located mainly in macrophages and Schwann cells by immuno-reactive staining. Similarly, there is local up-regulation of both TNFR1 and TNFR2 as injured neurons undergo Wallerian degeneration, albeit at differential rates. Similar results are found in humans, where nerve biopsies from patients with painful neuropathy show higher levels of TNF-α expression, especially in Schwann cells. Intra-sciatic injection of TNF-α in rats reproduces pain hypersensitivity that is similar to that of neuropathic pain in humans, and this is reversible with neutralizing antibodies to TNFR, in particular TNFR1. TNF-α enhances the tetrodotoxin-resistant (TTX-R) Na+ current in cultured DRG cells from wild-type but not from TNFR1-knockout mice, and such current is abolished by a p38-MAPK inhibitor; implying that TNF acts via TNFR1 and activates TTX-R Na+ channels via the p38 MAPK system. Further studies using TNFR1/TNFR2 knock-out mice have suggested a neurotoxic role for TNFR1 versus a neuroprotective role of TNFR2. However, there is still debate regarding the relative roles of TNFR1 and TNFR2 in chronic pain: in mice with tumor-induced thermal hyperalgesia, deletion of the TNFR2 gene reduces the painful response hence signifying a role for TNFR2; whilst in rats with spinal root injury, TNFR1 elicits excitatory responses in DRG of adjacent uninjured roots and TNFR2 excites DRG neurons from injured roots. In the inflammatory models of carrageenan-induced and zymosan-induced pleurisy in rat models, TNF-α has been found to have a lead role in activating a cascade of other cytokines, notably IL-1β, IL-6 and IL-8. A similar local cascade has been demonstrated in a model of neuropathic pain following nerve injury.

The role of TNF-α in peripheral mechanisms of neuropathic pain

TNF-α plays a role in the peripheral mediation of neuropathic pain. Clinically, HIV therapy and chemotherapy produce peripheral neuropathy with massive release of TNF-α in serum and TNF-α used as a clinical anti-cancer treatment leads to peripheral neuropathy. Traditional CCI of sciatic nerve in rats results in raised levels of TNF immunoreactivity in dorsal root ganglia (DRG) of both injured and uninjured ipsilateral adjacent afferents, as well as of contralateral uninjured counterparts, which can only be partly explained by retrograde axonal transport. There is also a corresponding up-regulation of TNFR1 and TNFR2 in both nerve and DRG, with a temporal pattern of increased TNF mRNA expression, first in sciatic nerve, and then in DRG. When nucleus pulposus extract of coccxygeal intervertebral disc is applied to lumbar DRG of rats, neuropathic pain is induced but is abolished by co-application of TNRF1, implying a direct role of TNF as a local mediator. Exogenous TNF-α injected into DRG of CCI roots is transported both anterograde to the site of injury and retrograde into the dorsal horn, precipitating allodynia in both the ligated and adjacent uninjured nerves. TNF-α is known to lead to apoptosis via TNFR1 and the caspase signaling pathway. Caspase inhibitors can attenuate peripheral neuropathy experimentally induced by HIV therapy or chemotherapy in rats. A recent study compared crush injury of L5 spinal nerve (distal to DRG) with L5 nerve roots (proximal to DRG) in rats and found that distal crush injury resulted in more neuronal apoptosis and enhanced TNF-α expression and caspase levels, correlating with higher neuropathic pain, lending more support to a TNF-α-apoptosis-caspase signaling paradigm for peripheral neuropathic pain. In addition to enhancing TTX-R Na+ channels in nociceptive DRG neurons, TNF-α can also increase membrane K+ ion conductance in a non-voltage-gated fashion leading to overall neuronal hyper-excitability and hence leading to neuropathic pain.

The role of TNF-α and glia in central mechanisms of neuropathic pain

In late 1990s, TNF-α was proposed to be one pro-inflammatory cytokine with a pivotal role in the "immune-to-brain" pathway of communication for pain, and in models of sickness response in general. In classic CCI models in rats, increased levels of TNF-α are found in hippocampus, locus coeruleus and red nucleus of brain. Recent data have suggested that TNF-α mediates central mechanisms of neuropathic pain through glial systems. In the central nervous system, glial cells outnumber neurons by as much as 50-fold, and include three relevant types: astrocytes, oligodendrocytes and microglia. Oligodendrocytes not only provide the myelin sheaths that insulate the neurons, they also contribute to the actual expansion of neuronal caliber and reorganization of neurofilaments. Astrocytes are the most abundant glial cells and possess the most diverse functions: they can modulate synaptic functions by forming a tripartite synapse with pre-synaptic, post-synaptic and extra-synaptic astrocytic contacts with up to 10,000 other neurons using glutamate and adenosine as neurotransmitters. It has been suggested that spinal astrocytes may play a role in sensitization of chronic pain via activation of the p38-MAPK system, and may even synapse with microglia, with pre-synaptic neuronal processes and with post-synaptic neuronal structures to form a tetrapartite configuration. Astrocytes also regulate maturation of neurons and synpatogenesis, hence playing a pivotal role in modulation of neural plasticity. Microglia constitute 15-20% of the total glial population and serve as an immune invigilator for the central nervous system. They originate from tmesodermal precursor cells of hemopoietic lineage. In response to nerve injury and inflammation, microglia transform into macrophage-like cells that express major histocompatibility complex antigens and secrete pro-inflammatory cytokines, including TNF-α, IL-1 and IL-6; CCL2 and CX3CL1, and ATP, which mediate their effects via the p38-mitogen-activated protein kinase (p38-MAPK) system.

Back in 1991, it was shown that classic CCI leads to hypertrophy of astroglia in the dorsal horn of spinal cord as reflected by increased immunostaining of glial fibrillary acidic protein. Since then, other subcutaneous and intraperitoneal inflammatory pain models have also been shown to induce glial activation. In newborn rats, where microglia are immature, intrathecal lipopolysaccharide (LPS) fails to evoke the allodynia response that is invariably seen in adult rats, suggesting a necessary role for functional microglia in the pathogenesis of neuropathic pain. Along with various other mediators, TNF-α has been shown to be present on the surfaces of astrocytes by immunofluorescence staining, where TNF-α auto-stimulates its own production via G-protein coupled receptor (CXCR4) and TNF-α converting enzyme. The result is a cascade of events leading typically to production of IL-1, IL-6, nitric oxide and ATP, all of which contribute to enhanced neuronal activity leading to pathological pain. Wei et al demonstrated increased levels of TNF-α and IL-1β in the rostral ventromedial medulla (RVM) of rats after CCI of the infraorbital nerve, with a corresponding enhancement of phosphorylation of the NR1 subunit of NMDA receptors, which is thought to be coupled to the receptors for both TNF-α and IL-1β. Injection of TNF-α and IL-1β into RVM increases NR1 phosphorylation of NMDA receptors and produces hyperalgesia, which is reversed by an NMDA antagonist. Wei's work sparked off research into NMDA receptors as a possible target for treating neuropathic pain; unfortunately, progress has been discouraged by the ubiquitous expression of NMDA receptors in the human central nervous system, which renders NMDA receptor blockade for analgesia an impossible task without concomitant alterations in cognition, memory and learning.

TNF-α, neural plasticity and neuropathic pain

Originally identified in hippocampus as a substrate for memory storage and learning, the synaptic mechanisms of long term potentiation (LTP) in glutamergic neurons have since been demonstrated as well in other parts of the central nervous system; in particular, in the dorsal horn of the spinal cord, where they may lead to abnormal nociception and neuropathic pain. Normal nociceptive signals are conveyed by both Aδ and C-fibers; of which the latter make synapses with second-order neurons in the spinal dorsal horn. The LTP phenomenon has been well characterised in C-fibers of rat dorsal horn with tetanic stimulation and also with acute nerve injury. High-frequency stimulation leads to an LTP pattern of cutaneous allodynia and hyperalgesia in humans with a typical early LTP time course. As the signalling mechanism of LTP unfolds, TNF-α is found to play an important role. Endogenous glial TNF-α can modulate synaptic plasticity by increasing the expression of AMPA receptors in cultured rat hippocampal slices for homeostatic regulation of synaptic strength in an activity-dependent fashion. However, TNF-α given at non-physiological levels often inhibits LTP in similar models of cultured rat hippocampus. As regards to C-fibers in the spinal dorsal horn, exogenous TNF-α produces LTP in C-fiber evoked field potentials only in the presence of nerve injury, and this LTP is blocked by inhibitors of NF-kappa B, JNK and p38-MAPK. In the absence of nerve injury, TNF-α can neutralise the action of src-family kinase inhibitors by restoring LTP in C-fiber evoked potentials as normally induced by high-frequency stimulation (HFS).

TNF-α, ATP and p38-MAPK

Since the 1950s, release of ATP has been detected from nerve endings and a role for ATP in nociception was implicated when it was shown to induce pain in human blister bases. ATP excites cutaneous afferent neurons of animal models in a fashion similar to that of other neurotransmitters like 5-HT and acetylcholine, and can act proximally to excite DRG neurons. Around the same time, Burnstock and his colleagues first characterized purinergic receptors into P1 (sensitive to adenosine, ADO), P2X, and P2Y receptors (sensitive to ATP and ADP). Molecular cloning studies have identified four sub-types of P1 (A1, A2A, A2B, and A3), seven sub-types of P2X (P2X1 to P2X7) and 8 sub-types of P2Y receptors (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, P2Y14). Each subtype has a different distribution in neuronal and glial cells, interacting with each other in an intricate manner. In terms of signaling functions, P1 and P2Y receptors are G-protein coupled receptors, while P2X receptors are ligand-gated ion channels. Within the context of neuropathic pain, P2X3, P2X4 and P2X7 receptors are thought to play a role; and in particular, P2X3 may act via the TTX-R voltage-gated sodium channel Nav 1.9.

Earlier studies using nerve injury models in rats revealed either an increase or decrease of P2X3 immuno-reactivity of the DRG neurons, depending on the type of nerve injury. When expression of P2X3 receptors in DRG is reduced using anti-sense oligonucleotides or siRNA, development of mechanical hyperalgesia is mitigated after classic CCI. Furthermore, administration of anti-sense oligonucleotides to knock down P2X3 receptors can reverse established neuropathic pain that re-emerges after cessation of the anti-sense treatment, suggesting a dynamic modulatory role of P2X3 receptors. Following a similar approach, Tsuda et al demonstrated an increase in P2X4 receptor expression after chronic nerve injury, and showed that both pharmacological blockade and anti-sense oligonucleotide treatment abrogates the development of mechanical allodynia. Later studies have suggested that P2X4 receptor stimulation leads to secretion of brain-derived neurotrophic factor (BDNF) in spinal microglia, and that this BDNF is involved in mediating neuropathic pain, possibly via activation of the p38-MAPK system. P2X7 receptors are associated with TNF-α production in microglia through the p38-MAPK system, as an inhibitor of MAPK system will suppress production of TNF-α mRNA and an inhibitor of p38 will prevent nucleocytoplamic transport of TNF-α mRNA. Independent of ATP, the p38-MAPK system seems to be essential for the action of TNF-α via TTX-R Na+ channels. As an entity itself, microglial p38-MAPK has been implicated in the pathogenesis of neuropathic pain in studies using various in vivo models of peripheral nerve and spinal cord injury. For example, spinal nerve ligation in rats leads to allodynia with concomitant rises in TNF-α and p38 phosphorylation; treatment with inhibitors of either TNF-α or p38 results in reduction of allodynia and, finally, TNF-α blockade can in turn suppress p38 activation. Studies using HSV-mediated gene transfer in nerve injury animal models have shown induced expression of soluble p55 TNFR (sTNFR2) in DRG neurons, resulting in decreased phosphorylation of p38 and reduced allodynia, again suggesting a causal link between TNF-α and the p38-MAPK system.

TNF-α as potential drug target for chronic pain--the possibilities

Due to the unique trimeric structure shared between the TNF ligand and the TNF receptor (both belonging to the TNF/TNFR SPF), the transmembrane portion of TNF molecule (mTNF), besides being a ligand, is capable of acting as a receptor for a soluble form of TNF (sTNF) in a "reverse-signaling" manner, which then inhibits phosphorylation of p38 and hence expression of TNF protein. This unique phenomenon makes it possible to use gene therapy with a herpes simplex virus vector carrying a p55 sTNFR gene to transfect DRG neurons of rats. As a result, over-expressed p55 sTNFR (sTNFR2) binds to the mTNF of DRG and down-regulates overall production of TNF by reverse signaling, significantly reducing the allodynia and hyperalgesia responses to CCI. Following a similar logic, a fusion protein (ELP-sTNFR2) has been developed wherein a soluble form of TNFR2 (sTNFR2) is conjugated to a temperature-sensitive elastin-like polypeptide (ELP), which can be thermally triggered to form a deposit around the peri-neural site of injection. This fusion protein has been reported to be able to mitigate levels of TNF-α in DRG of injured nerve in rat models. Indeed, many studies have demonstrated that local or spinal administration of agents that antagonize TNF-α will attenuate pain behaviors in neuropathic animal models. Mechanical allodynia in the rat model of central neuropathic pain due to T13 spinal cord hemisection is attenuated by immediate, but not delayed, intrathecal administration of etanercept (a fusion protein blocker of TNF-α) at 1-4 weeks post spinal cord injury. Propentofylline is a methylxanthine that inhibits lipopolysaccharide (LPS)-induced release of both TNF-α and IL-1β in a dose-dependent manner in glial cultures and abates allodynia in rat spinal nerve transection models by modulating glial activation. Propentofylline was initially evaluated for treating dementia, but was eventually withdrawn from further clinical studies due to patent issues, and its efficacy in animal neuropathic pain models has yet to be tested in humans. Thalidomide, once banned in 1963 due to its teratogenicity, is now regaining favor in neuropathic pain research due to its ability to cross the BBB and its inhibitory effects on TNF-α (in vitro and in-vivo) and on IL-1/IL-6 (in-vitro only). In the rat model of CCI, systemic thalidomide reduces the hyperalgesia response coincident with reductions in TNF-α levels, unchanged levels of IL-1/IL-6 and increased levels of IL-10. Clinically, there have been sporadic reports of success in using thalidomide to treat complex regional pain syndromes. However, the balance of thalidomide's efficacy versus safety in treating in chronic and neuropathic pain needs further clinical study, especially in view of its paradoxical neurotoxicity. Methotrexate is a well-known drug for treating cancer that is derived from glutamic acid. It is capable of crossing the BBB and has anti-rheumatoid and anti-inflammatory actions through its inhibition of production of TNF-α via adenosine nucleotides and its ability to antagonize the actions of IL-1. Intrathecal administration of methotrexate reduces classic CCI-induced allodynia in rats but its value in treating neuropathic pain is severely offset by its propensity per se to induce astrocytic proliferation and hence neurotoxicity.

The role of TNF-α in chronic pain seems irrefutable in view of abundant data from various neuropathic animal models, and with the actual isolation of TNF-α from neuropathic nerves and perineural fat from radiculopathic nerve roots in humans. An initial pilot study using subcutaneous etanercept to treat patients admitted to the hospital with acute severe sciatica showed improved pain scores. Similarly, an open-label study with infliximab (an antibody to TNF-α) revealed promising results. Subsequent randomized controlled trials failed to support the benefits of systemic anti-TNF-α treatment, but a recent report did show positive benefits of epidurally administered etanercept in the treatment of sciatica. To date we are unaware of any randomized controlled clinical trials of infliximab or etanercept in treating other types of neuropathic pain. AV411(ibudilast), a trial drug that was originally developed as a non-selective phosphodiesterase inhibitor for treating bronchial asthma, has been studied in phase I and phase 2a clinical trials in the US and in Australia for treatment of diabetic neuropathic pain, based on findings that AV411 also suppresses glial cell activation and reduces the production of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) in rat neuropathic pain model.

Perspective on future studies

TNF-α is undoubtedly a titan in the research of neuropathic pain, and is by no means the only one in the arena. It is a pivotal member of the cytokine mediator system that is intrinsic to the pathogenesis of neuropathic pain both at peripheral and central levels (See Fig 1). Together with other mediators like interleukins, nerve growth factors, chemokines and interferons, it forms a network that interacts with downstream signaling mechanisms like the NMDA, ATP and MAPK systems. We now know that removing TNF-α from the picture will not abolish neuropathic pain as has already been demonstrated by the failure of TNF-α antagonists in clinical trials for sciatica. Emerging data have guided research towards a collective role for glia-derived mediators and their coupled signaling pathways in the modulation of neuropathic pain. The paradigm is shifting from a single compound towards a system as a potential target for novel drug development for treating neuropathic pain. Examples include the chemokine system, the MAPK system, and the glial system as a whole.

Abbreviations

5-HT: 5-hydroxytryptamine (Serotonin); ADO: Adenosine; ADP: Adenosine diphosphate; ATP: Adenosine triphosphate; BBB: Blood-brain barrier; BDNF: Brain-derived neurotrophic factor; CCI: Chronic constrictive injury; CCL2: Chemokine (C-C motif) ligand-2; CX3CL1: Chemokine (C-X3-C motif) ligand 1; CXCR4: CXC chemokine receptor-4; DRG: Dorsal root ganglion; CRDs: Cysteine rich domains; ELP: Elastin-like polypeptide; ERK: Extracellular signal-regulated kinases; HFS: High Frequency stimulation; HSV: Herpes simplex virus; IL-1: Interleukin-1; IL-1β: Interleukin-1 beta; IL-6: Interleukin-6; IL-8: Interleukin-8; IL-10: Interleukin-10; JNK: c-Jun N-terminal kinases; LPS: Lipopolysaccaride; LTP: Long Term Potentiation; MAPK: Mitogen activated protein kinase; NMDA: N-methyl-D-aspartic acid; NSAIDs: Non-steroidal anti-inflammatory drugs; siRNA: Small interfering RNA; RVM: Rostral ventromedial medulla; THD: TNF homology domain; mTNF: Transmembrane portion of TNF; sTNF: Soluble form of TNF; TNF-α: Tumor necrosis factor alpha; TNFR: Tumor necrosis factor receptor; sTNFR2: Soluble p55 TNF receptor; TNFR SFR: Tumor necrosis factor receptor super family receptor; TTX-R: Tetrodotoxin resistant.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

LL wrote the manuscript, CMC provided comments and proof-reading. Both authors have read and approved of the final version of the manuscript.

References 217

  1. 1.

    Campbell JN Meyer RA Mechanisms of neuropathic painNeuron2006 527792

    Not in our library10.1016/j.neuron.2006.09.021

  2. 2.

    McMahon SB Cafferty WB Marchand F Immune and glial cell factors as pain mediators and modulatorsExp Neurol2005 192444462

    Not in our library10.1016/j.expneurol.2004.11.001

  3. 3.

    Marchand F Perretti M McMahon SB Role of the immune system in chronic painNat Rev Neurosci2005 6521532

    Not in our library10.1038/nrn1700

  4. 4.

    Moalem G Tracey DJ Immune and inflammatory mechanisms in neuropathic painBrain Res Rev2006 51240264

    Not in our library10.1016/j.brainresrev.2005.11.004

  5. 5.

    Bowsher D Neurogenic pain syndromes and their managementBr Med Bull1991 47644666

    Not in our library10.1093/oxfordjournals.bmb.a072498

  6. 6.

    Cartier GT Galer BS Advances in the management of neuropathic pain. [Phys Med Rehabil Clin N Am. 2001] - PubMed resultPhys Med Rehabil Clin N Am2001 12447459

    Not in our library

  7. 7.

    Toth C Lander J Wiebe S The prevalence and impact of chronic pain with neuropathic pain symptoms in the general populationPain Med2009 10918929

    Not in our library10.1111/j.1526-4637.2009.00655.x

  8. 8.

    Mitchell SW Injuries of nerves and their consequences. Philadelphia, Lippincott1872

    Not in our library

  9. 9.

    Hall GC Carroll D Parry D McQuay HJ Epidemiology and treatment of neuropathic pain: the UK primary care perspectivePain2006 122156162

    Not in our library10.1016/j.pain.2006.01.030

  10. 10.

    McDermott AM Toelle TR Rowbotham DJ Schaefer CP Dukes EM The burden of neuropathic pain: results from a cross-sectional surveyEur J Pain2006 10127135

    Not in our library10.1016/j.ejpain.2005.01.014

  11. 11.

    O'Connor AB Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapyPharmacoeconomics2009 2795112

    Not in our library10.2165/00019053-200927020-00002

  12. 12.

    Bennett GJ Xie YK A peripheral mononeuropathy in rat that produces d... [Pain. 1988] - PubMed resultPain1988 3387107

    Not in our library10.1016/0304-3959(88)90209-6

  13. 13.

    Xie Y Zhang J Petersen M LaMotte RH Functional changes in dorsal root ganglion cells after chronic nerve constriction in the ratJ Neurophysiol1995 7318111820

    Not in our library10.1152/jn.1995.73.5.1811

  14. 14.

    Kingery WS Castellote JM Wang EE A loose ligature-induced mononeuropathy produces h... [Pain. 1993] - PubMed resultPain1993 55297304

    Not in our library10.1016/0304-3959(93)90004-9

  15. 15.

    Kim KJ Yoon YW Chung JM Comparison of three rodent neuropathic pain modelsExp Brain Res1997 113200206

    Not in our library10.1007/bf02450318

  16. 16.

    Shir Y Seltzer Z A-fibers mediate mechanical hyperesthesia and allo... [Neurosci Lett. 1990] - PubMed resultNeurosci Lett1990 1156267

    Not in our library10.1016/0304-3940(90)90518-e

  17. 17.

    Seltzer Z Dubner R Shir Y A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injuryPain1990 43205218

    Not in our library10.1016/0304-3959(90)91074-s

  18. 18.

    Nuytten D Kupers R Lammens M Dom R Further evidence for myelinated as well as unmyeli... [Exp Brain Res. 1992] - PubMed resultExp Brain Res1992 917378

    Not in our library10.1007/bf00230014

  19. 19.

    Puke MJ Xu XJ Wiesenfeld-Hallin Z Intrathecal administration of clonidine suppresses... [Neurosci Lett. 1991] - PubMed resultNeurosci Lett1991 133199202

    Not in our library10.1016/0304-3940(91)90569-f

  20. 20.

    Miao P Madec K Gong Y Shen H Eisenstat D Melanson M Gu X Leong C Klowak M Namaka M Axotomy-induced up-regulation of tumor necrosis factor-alpha in the dorsal root gangliaNeurol Res2008 30623631

    Not in our library10.1179/174313208x289606

  21. 21.

    Guedes RP Araujo AS Janner D Bello-Klein A Ribeiro MF Partata WA Increase in reactive oxygen species and activation of Akt signaling pathway in neuropathic painCell Mol Neurobiol2008 2810491056

    Not in our library10.1007/s10571-008-9279-9

  22. 22.

    Li L Xian CJ Zhong JH Zhou XF Effect of lumbar 5 ventral root transection on pain behaviors: a novel rat model for neuropathic pain without axotomy of primary sensory neuronsExp Neurol2002 1752334

    Not in our library10.1006/exnr.2002.7897

  23. 23.

    Xu JT Xin WJ Zang Y Wu CY Liu XG The role of tumor necrosis factor-alpha in the neuropathic pain induced by Lumbar 5 ventral root transection in ratPain2006 123306321

    Not in our library10.1016/j.pain.2006.03.011

  24. 24.

    Olsson Y Degranulation of mast cells in peripheral nerve injuriesActa Neurol Scand1967 43365374

    Not in our library10.1111/j.1600-0404.1967.tb05739.x

  25. 25.

    Perry VH Brown MC Gordon S The macrophage response to central and peripheral nerve injury. A possible role for macrophages in regenerationJ Exp Med1987 16512181223

    Not in our library10.1084/jem.165.4.1218

  26. 26.

    Daemen MA Kurvers HA Kitslaar PJ Slaaf DW Bullens PH Wildenberg FA Van den Neurogenic inflammation in an animal model of neuropathic painNeurol Res1998 204145

    Not in our library10.1080/01616412.1998.11740483

  27. 27.

    Maves TJ Pechman PS Gebhart GF Meller ST Possible chemical contribution from chromic gut sutures produces disorders of pain sensation like those seen in manPain1993 545769

    Not in our library10.1016/0304-3959(93)90100-4

  28. 28.

    Sommer C Galbraith JA Heckman HM Myers RR Pathology of experimental compression neuropathy producing hyperesthesiaJ Neuropathol Exp Neurol1993 52223233

    Not in our library10.1097/00005072-199305000-00006

  29. 29.

    Frisen J Risling M Fried K Distribution and axonal relations of macrophages in a neuromaNeuroscience1993 5510031013

    Not in our library10.1016/0306-4522(93)90314-6

  30. 30.

    Clatworthy AL Illich PA Castro GA Walters ET Role of peri-axonal inflammation in the development of thermal hyperalgesia and guarding behavior in a rat model of neuropathic painNeurosci Lett1995 18458

    Not in our library10.1016/0304-3940(94)11154-b

  31. 31.

    Schafers M Marziniak M Sorkin LS Yaksh TL Sommer C Cyclooxygenase inhibition in nerve-injury- and TNF-induced hyperalgesia in the ratExp Neurol2004 185160168

    Not in our library10.1016/j.expneurol.2003.09.015

  32. 32.

    Ma W Du W Eisenach JC Role for both spinal cord COX-1 and COX-2 in maintenance of mechanical hypersensitivity following peripheral nerve injuryBrain Res2002 9379499

    Not in our library10.1016/s0006-8993(02)02593-3

  33. 33.

    Syriatowicz JP Hu D Walker JS Tracey DJ Hyperalgesia due to nerve injury: role of prostaglandinsNeuroscience1999 94587594

    Not in our library10.1016/s0306-4522(99)00365-6

  34. 34.

    Okubo M Yamanaka H Kobayashi K Noguchi K Leukotriene synthases and the receptors induced by peripheral nerve injury in the spinal cord contribute to the generation of neuropathic painGlia2009 585599610

    Not in our library10.1002/glia.20948

  35. 35.

    Rashid MH Inoue M Matsumoto M Ueda H Switching of bradykinin-mediated nociception following partial sciatic nerve injury in miceJ Pharmacol Exp Ther2004 30811581164

    Not in our library10.1124/jpet.103.060335

  36. 36.

    Petcu M Dias JP Ongali B Thibault G Neugebauer W Couture R Role of kinin B1 and B2 receptors in a rat model of neuropathic painInt Immunopharmacol2008 8188196

    Not in our library10.1016/j.intimp.2007.09.009

  37. 37.

    Berrocoso E De Benito MD Mico JA Role of serotonin 5-HT1A and opioid receptors in the antiallodynic effect of tramadol in the chronic constriction injury model of neuropathic pain in ratsPsychopharmacology (Berl)2007 19397105

    Not in our library10.1007/s00213-007-0761-8

  38. 38.

    Faerber L Drechsler S Ladenburger S Gschaidmeier H Fischer W The neuronal 5-HT3 receptor network after 20 years of research--evolving concepts in management of pain and inflammationEur J Pharmacol2007 56018

    Not in our library10.1016/j.ejphar.2007.01.028

  39. 39.

    Rahman W Suzuki R Webber M Hunt SP Dickenson AH Depletion of endogenous spinal 5-HT attenuates the behavioural hypersensitivity to mechanical and cooling stimuli induced by spinal nerve ligationPain2006 123264274

    Not in our library10.1016/j.pain.2006.02.033

  40. 40.

    Inoue K P2 receptors and chronic painPurinergic Signal2007 3135144

    Not in our library10.1007/s11302-006-9045-8

  41. 41.

    Inoue K Tsuda M Koizumi S ATP- and adenosine-mediated signaling in the central nervous system: chronic pain and microglia: involvement of the ATP receptor P2X4J Pharmacol Sci2004 94112114

    Not in our library10.1254/jphs.94.112

  42. 42.

    Inoue K Tsuda M Tozaki-Saitoh H Modification of neuropathic pain sensation through microglial ATP receptorsPurinergic Signal2007 3311316

    Not in our library10.1007/s11302-007-9071-1

  43. 43.

    Wilson-Gerwing TD Stucky CL McComb GW Verge VM Neurotrophin-3 significantly reduces sodium channel expression linked to neuropathic pain statesExp Neurol2008 213303314

    Not in our library10.1016/j.expneurol.2008.06.002

  44. 44.

    Coull JA Beggs S Boudreau D Boivin D Tsuda M Inoue K Gravel C Salter MW De Koninck Y BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic painNature2005 43810171021

    Not in our library10.1038/nature04223

  45. 45.

    Boudes M Menigoz A Non-neuronal BDNF, a key player in development of central sensitization and neuropathic painJ Physiol2009 58721112112

    Not in our library10.1113/jphysiol.2009.172130

  46. 46.

    Chien CC Fu WM Huang HI Lai YH Tsai YF Guo SL Wu TJ Ling QD Expression of neurotrophic factors in neonatal rats after peripheral inflammationJ Pain2007 8161167

    Not in our library10.1016/j.jpain.2006.07.004

  47. 47.

    Sommer C Kress M Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesiaNeurosci Lett2004 361184187

    Not in our library10.1016/j.neulet.2003.12.007

  48. 48.

    Okamoto K Martin DP Schmelzer JD Mitsui Y Low PA Pro- and anti-inflammatory cytokine gene expression in rat sciatic nerve chronic constriction injury model of neuropathic painExp Neurol2001 169386391

    Not in our library10.1006/exnr.2001.7677

  49. 49.

    Arruda JL Colburn RW Rickman AJ Rutkowski MD DeLeo JA Increase of interleukin-6 mRNA in the spinal cord following peripheral nerve injury in the rat: potential role of IL-6 in neuropathic painBrain Res Mol Brain Res1998 62228235

    Not in our library10.1016/s0169-328x(98)00257-5

  50. 50.

    Sommer C Schmidt C George A Hyperalgesia in experimental neuropathy is dependent on the TNF receptor 1Exp Neurol1998 151138142

    Not in our library10.1006/exnr.1998.6797

  51. 51.

    Watkins LR Maier SF Goehler LE Immune activation: the role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain statesPain1995 63289302

    Not in our library10.1016/0304-3959(95)00186-7

  52. 52.

    Latremoliere A Mauborgne A Masson J Bourgoin S Kayser V Hamon M Pohl M Differential implication of proinflammatory cytokine interleukin-6 in the development of cephalic versus extracephalic neuropathic pain in ratsJ Neurosci2008 2884898501

    Not in our library10.1523/jneurosci.2552-08.2008

  53. 53.

    White FA Jung H Miller RJ Chemokines and the pathophysiology of neuropathic painProc Natl Acad Sci USA2007 1042015120158

    Not in our library10.1073/pnas.0709250104

  54. 54.

    Ma W Quirion R Inflammatory mediators modulating the transient receptor potential vanilloid 1 receptor: therapeutic targets to treat inflammatory and neuropathic painExpert Opin Ther Targets2007 11307320

    Not in our library10.1517/14728222.11.3.307

  55. 55.

    Gao X Kim HK Chung JM Chung K Reactive oxygen species (ROS) are involved in enhancement of NMDA-receptor phosphorylation in animal models of painPain2007 131262271

    Not in our library10.1016/j.pain.2007.01.011

  56. 56.

    Siniscalco D Fuccio C Giordano C Ferraraccio F Palazzo E Luongo L Rossi F Roth KA Maione S de Novellis V Role of reactive oxygen species and spinal cord apoptotic genes in the development of neuropathic painPharmacol Res2007 55158166

    Not in our library10.1016/j.phrs.2006.11.009

  57. 57.

    Bergsteinsdottir K Kingston A Jessen KR Rat Schwann cells can be induced to express major histocompatibility complex class II molecules in vivoJ Neurocytol1992 21382390

    Not in our library10.1007/bf01191706

  58. 58.

    Constable AL Armati PJ Toyka KV Hartung HP Production of prostanoids by Lewis rat Schwann cells in vitroBrain Res1994 6357580

    Not in our library10.1016/0006-8993(94)91425-7

  59. 59.

    Bolin LM Verity AN Silver JE Shooter EM Abrams JS Interleukin-6 production by Schwann cells and induction in sciatic nerve injuryJ Neurochem1995 64850858

    Not in our library10.1046/j.1471-4159.1995.64020850.x

  60. 60.

    Adler JE Nico L VandeVord P Skoff AM Modulation of neuropathic pain by a glial-derived factorPain Med2009 1012291236

    Not in our library10.1111/j.1526-4637.2009.00708.x

  61. 61.

    Hansson E Could chronic pain and spread of pain sensation be induced and maintained by glial activation?Acta Physiol (Oxf)2006 187321327

    Not in our library10.1111/j.1748-1716.2006.01568.x

  62. 62.

    Moss A Beggs S Vega-Avelaira D Costigan M Hathway GJ Salter MW Fitzgerald M Spinal microglia and neuropathic pain in young ratsPain2007 128215224

    Not in our library10.1016/j.pain.2006.09.018

  63. 63.

    Thacker MA Clark AK Bishop T Grist J Yip PK Moon LD Thompson SW Marchand F McMahon SB CCL2 is a key mediator of microglia activation in neuropathic pain statesEur J Pain2009 13263272

    Not in our library10.1016/j.ejpain.2008.04.017

  64. 64.

    Sauder DN The role of epidermal cytokines in inflammatory skin diseasesJ Invest Dermatol1990 9527S28S

    Not in our library10.1111/1523-1747.ep12505705

  65. 65.

    Compston A Zajicek J Sussman J Webb A Hall G Muir D Shaw C Wood A Scolding N Glial lineages and myelination in the central nervous systemJ Anat1997 190Pt 2161200

    Not in our library10.1046/j.1469-7580.1997.19020161.x

  66. 66.

    Lisak RP Skundric D Bealmear B Ragheb S The role of cytokines in Schwann cell damage, protection, and repairJ Infect Dis1997 176Suppl 2S173179

    Not in our library10.1086/513788

  67. 67.

    Beeson PB Temperature-elevating effect of a substance obtained from polymorphonuclear leucocytesJ Clin Invest1948 27524

    Not in our library

  68. 68.

    Uceyler N Sommer C Cytokine regulation in animal models of neuropathic pain and in human diseasesNeurosci Lett2008 437194198

    Not in our library10.1016/j.neulet.2008.03.050

  69. 69.

    Wagner R Myers RR Endoneurial injection of TNF-alpha produces neuropathic pain behaviorsNeuroreport1996 728972901

    Not in our library10.1097/00001756-199611250-00018

  70. 70.

    Wagner R Myers RR Schwann cells produce tumor necrosis factor alpha: expression in injured and non-injured nervesNeuroscience1996 73625629

    Not in our library10.1016/0306-4522(96)00127-3

  71. 71.

    Zelenka M Schafers M Sommer C Intraneural injection of interleukin-1beta and tumor necrosis factor-alpha into rat sciatic nerve at physiological doses induces signs of neuropathic painPain2005 116257263

    Not in our library10.1016/j.pain.2005.04.018

  72. 72.

    Sweitzer SM Colburn RW Rutkowski M DeLeo JA Acute peripheral inflammation induces moderate glial activation and spinal IL-1beta expression that correlates with pain behavior in the ratBrain Res1999 829209221

    Not in our library10.1016/s0006-8993(99)01326-8

  73. 73.

    DeLeo JA Colburn RW Nichols M Malhotra A Interleukin-6-mediated hyperalgesia/allodynia and increased spinal IL-6 expression in a rat mononeuropathy modelJ Interferon Cytokine Res1996 16695700

    Not in our library10.1089/jir.1996.16.695

  74. 74.

    Wells MR Racis SP Jr Vaidya U Changes in plasma cytokines associated with peripheral nerve injuryJ Neuroimmunol1992 39261268

    Not in our library10.1016/0165-5728(92)90260-r

  75. 75.

    Bickels J Kollender Y Merinsky O Meller I Coley's toxin: historical perspectiveIsr Med Assoc J2002 4471472

    Not in our library

  76. 76.

    Carswell EA Old LJ Kassel RL Green S Fiore N Williamson B An endotoxin-induced serum factor that causes necrosis of tumorsProc Natl Acad Sci USA1975 7236663670

    Not in our library10.1073/pnas.72.9.3666

  77. 77.

    Bodmer JL Schneider P Tschopp J The molecular architecture of the TNF superfamilyTrends Biochem Sci2002 271926

    Not in our library10.1016/s0968-0004(01)01995-8

  78. 78.

    Locksley RM Killeen N Lenardo MJ The TNF and TNF receptor superfamilies: integrating mammalian biologyCell2001 104487501

    Not in our library10.1016/s0092-8674(01)00237-9

  79. 79.

    George A Schmidt C Weishaupt A Toyka KV Sommer C Serial determination of tumor necrosis factor-alpha content in rat sciatic nerve after chronic constriction injuryExp Neurol1999 160124132

    Not in our library10.1006/exnr.1999.7193

  80. 80.

    George A Buehl A Sommer C Wallerian degeneration after crush injury of rat sciatic nerve increases endo- and epineurial tumor necrosis factor-alpha proteinNeurosci Lett2004 372215219

    Not in our library10.1016/j.neulet.2004.09.075

  81. 81.

    Shubayev VI Myers RR Upregulation and interaction of TNFalpha and gelatinases A and B in painful peripheral nerve injuryBrain Res2000 8558389

    Not in our library10.1016/s0006-8993(99)02321-5

  82. 82.

    Sommer C Schafers M Painful mononeuropathy in C57BL/Wld mice with delayed wallerian degeneration: differential effects of cytokine production and nerve regeneration on thermal and mechanical hypersensitivityBrain Res1998 784154162

    Not in our library10.1016/s0006-8993(97)01327-9

  83. 83.

    Shamash S Reichert F Rotshenker S The cytokine network of Wallerian degeneration: tumor necrosis factor-alpha, interleukin-1alpha, and interleukin-1betaJ Neurosci2002 2230523060

    Not in our library10.1523/jneurosci.22-08-03052.2002

  84. 84.

    George A Buehl A Sommer C Tumor necrosis factor receptor 1 and 2 proteins are differentially regulated during Wallerian degeneration of mouse sciatic nerveExp Neurol2005 192163166

    Not in our library10.1016/j.expneurol.2004.11.002

  85. 85.

    Empl M Renaud S Erne B Fuhr P Straube A Schaeren-Wiemers N Steck AJ TNF-alpha expression in painful and nonpainful neuropathiesNeurology2001 5613711377

    Not in our library10.1212/wnl.56.10.1371

  86. 86.

    Sorkin LS Doom CM Epineurial application of TNF elicits an acute mechanical hyperalgesia in the awake ratJ Peripher Nerv Syst2000 596100

    Not in our library10.1046/j.1529-8027.2000.00012.x

  87. 87.

    Jin X Gereau RWt Acute p38-mediated modulation of tetrodotoxin-resistant sodium channels in mouse sensory neurons by tumor necrosis factor-alphaJ Neurosci2006 26246255

    Not in our library10.1523/jneurosci.3858-05.2006

  88. 88.

    Yang L Lindholm K Konishi Y Li R Shen Y Target depletion of distinct tumor necrosis factor receptor subtypes reveals hippocampal neuron death and survival through different signal transduction pathwaysJ Neurosci2002 2230253032

    Not in our library10.1523/jneurosci.22-08-03025.2002

  89. 89.

    Constantin CE Mair N Sailer CA Andratsch M Xu ZZ Blumer MJ Scherbakov N Davis JB Bluethmann H Ji RR Kress M Endogenous tumor necrosis factor alpha (TNFalpha) requires TNF receptor type 2 to generate heat hyperalgesia in a mouse cancer modelJ Neurosci2008 2850725081

    Not in our library10.1523/jneurosci.4476-07.2008

  90. 90.

    Schafers M Sommer C Geis C Hagenacker T Vandenabeele P Sorkin LS Selective stimulation of either tumor necrosis factor receptor differentially induces pain behavior in vivo and ectopic activity in sensory neurons in vitroNeuroscience2008 157414423

    Not in our library10.1016/j.neuroscience.2008.08.067

  91. 91.

    Ohishi S [Evaluation of time course and inter-relationship of inflammatory mediators in experimental inflammatory reaction]Yakugaku Zasshi2000 120455462

    Not in our library

  92. 92.

    Tonini G Santini D Vincenzi B Borzomati D Dicuonzo G La Cesa A Onori N Coppola R Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patientsJ Biol Regul Homeost Agents2002 16105109

    Not in our library

  93. 93.

    Drory VE Lev D Groozman GB Gutmann M Klausner JM Neurotoxicity of isolated limb perfusion with tumor necrosis factorJ Neurol Sci1998 15814

    Not in our library10.1016/s0022-510x(98)00098-7

  94. 94.

    Schafers M Geis C Svensson CI Luo ZD Sommer C Selective increase of tumour necrosis factor-alpha in injured and spared myelinated primary afferents after chronic constrictive injury of rat sciatic nerveEur J Neurosci2003 17791804

    Not in our library10.1046/j.1460-9568.2003.02504.x

  95. 95.

    Jancalek R Dubovy P Svizenska I Klusakova I Bilateral changes of TNF-alpha and IL-10 protein in the lumbar and cervical dorsal root ganglia following a unilateral chronic constriction injury of the sciatic nerveJ Neuroinflammation2010 711

    Not in our library10.1186/1742-2094-7-11

  96. 96.

    Shubayev VI Myers RR Axonal transport of TNF-alpha in painful neuropathy: distribution of ligand tracer and TNF receptorsJ Neuroimmunol2001 1144856

    Not in our library10.1016/s0165-5728(00)00453-7

  97. 97.

    Schafers M Sorkin LS Geis C Shubayev VI Spinal nerve ligation induces transient upregulation of tumor necrosis factor receptors 1 and 2 in injured and adjacent uninjured dorsal root ganglia in the ratNeurosci Lett2003 347179182

    Not in our library10.1016/s0304-3940(03)00695-5

  98. 98.

    Sacerdote P Franchi S Trovato AE Valsecchi AE Panerai AE Colleoni M Transient early expression of TNF-alpha in sciatic nerve and dorsal root ganglia in a mouse model of painful peripheral neuropathyNeurosci Lett2008 436210213

    Not in our library10.1016/j.neulet.2008.03.023

  99. 99.

    Cuellar JM Montesano PX Carstens E Role of TNF-alpha in sensitization of nociceptive dorsal horn neurons induced by application of nucleus pulposus to L5 dorsal root ganglion in ratsPain2004 110578587

    Not in our library10.1016/j.pain.2004.03.029

  100. 100.

    Shubayev VI Myers RR Anterograde TNF alpha transport from rat dorsal root ganglion to spinal cord and injured sciatic nerveNeurosci Lett2002 32099101

    Not in our library10.1016/s0304-3940(02)00010-1

  101. 101.

    Schafers M Lee DH Brors D Yaksh TL Sorkin LS Increased sensitivity of injured and adjacent uninjured rat primary sensory neurons to exogenous tumor necrosis factor-alpha after spinal nerve ligationJ Neurosci2003 2330283038

    Not in our library10.1523/jneurosci.23-07-03028.2003

  102. 102.

    Thorburn A Death receptor-induced cell killingCell Signal2004 16139144

    Not in our library10.1016/j.cellsig.2003.08.007

  103. 103.

    Micheau O Tschopp J Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexesCell2003 114181190

    Not in our library10.1016/s0092-8674(03)00521-x

  104. 104.

    Joseph EK Levine JD Caspase signalling in neuropathic and inflammatory pain in the ratEur J Neurosci2004 2028962902

    Not in our library10.1111/j.1460-9568.2004.03750.x

  105. 105.

    Sekiguchi M Sekiguchi Y Konno S Kobayashi H Homma Y Kikuchi S Comparison of neuropathic pain and neuronal apoptosis following nerve root or spinal nerve compressionEur Spine J2009 1819781985

    Not in our library10.1007/s00586-009-1064-z

  106. 106.

    Czeschik JC Hagenacker T Schafers M Busselberg D TNF-alpha differentially modulates ion channels of nociceptive neuronsNeurosci Lett2008 434293298

    Not in our library10.1016/j.neulet.2008.01.070

  107. 107.

    Watkins LR Maier SF The pain of being sick: implications of immune-to-brain communication for understanding painAnnu Rev Psychol2000 512957

    Not in our library10.1146/annurev.psych.51.1.29

  108. 108.

    Ignatowski TA Covey WC Knight PR Severin CM Nickola TJ Spengler RN Brain-derived TNFalpha mediates neuropathic painBrain Res1999 8417077

    Not in our library10.1016/s0006-8993(99)01782-5

  109. 109.

    Covey WC Ignatowski TA Knight PR Spengler RN Brain-derived TNFalpha: involvement in neuroplastic changes implicated in the conscious perception of persistent painBrain Res2000 859113122

    Not in our library10.1016/s0006-8993(00)01965-x

  110. 110.

    Covey WC Ignatowski TA Renauld AE Knight PR Nader ND Spengler RN Expression of neuron-associated tumor necrosis factor alpha in the brain is increased during persistent painReg Anesth Pain Med2002 27357366

    Not in our library10.1053/rapm.2002.31930

  111. 111.

    Li X Wang J Wang Z Dong C Dong X Jing Y Yuan Y Fan G Tumor necrosis factor-alpha of Red nucleus involved in the development of neuropathic allodyniaBrain Res Bull2008 in press

    Not in our library10.1016/j.brainresbull.2008.08.025

  112. 112.

    Sanchez I Hassinger L Paskevich PA Shine HD Nixon RA Oligodendroglia regulate the regional expansion of axon caliber and local accumulation of neurofilaments during development independently of myelin formationJ Neurosci1996 1650955105

    Not in our library10.1523/jneurosci.16-16-05095.1996

  113. 113.

    Nadkarni S Jung P Modeling synaptic transmission of the tripartite synapsePhys Biol2007 419

    Not in our library10.1088/1478-3975/4/1/001

  114. 114.

    Stevens B Neuron-astrocyte signaling in the development and plasticity of neural circuitsNeurosignals2008 16278288

    Not in our library10.1159/000123038

  115. 115.

    Haydon PG Carmignoto G Astrocyte control of synaptic transmission and neurovascular couplingPhysiol Rev2006 8610091031

    Not in our library10.1152/physrev.00049.2005

  116. 116.

    Ji RR Kawasaki Y Zhuang ZY Wen YR Decosterd I Possible role of spinal astrocytes in maintaining chronic pain sensitization: review of current evidence with focus on bFGF/JNK pathwayNeuron Glia Biol2006 2259269

    Not in our library10.1017/s1740925x07000403

  117. 117.
    p38 MAPK, Microglial Signaling, and Neuropathic Pain · 2007
    No notice
  118. 118.

    De Leo JA Tawfik VL LaCroix-Fralish ML The tetrapartite synapse: path to CNS sensitization and chronic painPain2006 1221721

    Not in our library10.1016/j.pain.2006.02.034

  119. 119.

    Seth P Koul N Astrocyte, the star avatar: redefinedJ Biosci2008 33405421

    Not in our library10.1007/s12038-008-0060-5

  120. 120.

    Vilhardt F Microglia: phagocyte and glia cellInt J Biochem Cell Biol2005 371721

    Not in our library10.1016/j.biocel.2004.06.010

  121. 121.

    Watkins LR Maier SF Glia: a novel drug discovery target for clinical painNat Rev Drug Discov2003 2973985

    Not in our library10.1038/nrd1251

  122. 122.

    Ren K Dubner R Neuron-glia crosstalk gets serious: role in pain hypersensitivityCurr Opin Anaesthesiol2008 21570579

    Not in our library10.1097/aco.0b013e32830edbdf

  123. 123.

    Abbadie C Bhangoo S De Koninck Y Malcangio M Melik-Parsadaniantz S White FA Chemokines and pain mechanismsBrain Res Rev2008 60112534

    Not in our library10.1016/j.brainresrev.2008.12.002

  124. 124.

    Inoue K Tsuda M Koizumi S Chronic pain and microglia: the role of ATPNovartis Found Symp2004 2615564discussion 64-57, 149-154full_text

    Not in our library

  125. 125.

    Tsuda M Inoue K [Neuropathic pain and ATP receptors in spinal microglia]Brain Nerve2007 59953959

    Not in our library

  126. 126.

    Garrison CJ Dougherty PM Kajander KC Carlton SM Staining of glial fibrillary acidic protein (GFAP) in lumbar spinal cord increases following a sciatic nerve constriction injuryBrain Res1991 56517

    Not in our library10.1016/0006-8993(91)91729-k

  127. 127.

    Watkins LR Milligan ED Maier SF Glial activation: a driving force for pathological painTrends Neurosci2001 24450455

    Not in our library10.1016/s0166-2236(00)01854-3

  128. 128.

    Watkins LR Hutchinson MR Milligan ED Maier SF "Listening" and "talking" to neurons: implications of immune activation for pain control and increasing the efficacy of opioidsBrain Res Rev2007 56148169

    Not in our library10.1016/j.brainresrev.2007.06.006

  129. 129.

    Wei F Guo W Zou S Ren K Dubner R Supraspinal glial-neuronal interactions contribute to descending pain facilitationJ Neurosci2008 281048210495

    Not in our library10.1523/jneurosci.3593-08.2008

  130. 130.

    Bliss TV Collingridge GL A synaptic model of memory: long-term potentiation in the hippocampusNature1993 3613139

    Not in our library10.1038/361031a0

  131. 131.

    Rygh LJ Svendsen F Fiska A Haugan F Hole K Tjolsen A Long-term potentiation in spinal nociceptive systems--how acute pain may become chronicPsychoneuroendocrinology2005 30959964

    Not in our library10.1016/j.psyneuen.2005.04.007

  132. 132.

    Ikeda H Kiritoshi T Murase K Synaptic plasticity in the spinal dorsal hornNeurosci Res2009 64133136

    Not in our library10.1016/j.neures.2009.03.004

  133. 133.

    Liu XG Sandkuhler J Long-term potentiation of C-fiber-evoked potentials in the rat spinal dorsal horn is prevented by spinal N-methyl-D-aspartic acid receptor blockageNeurosci Lett1995 1914346

    Not in our library10.1016/0304-3940(95)11553-0

  134. 134.

    Liu X Sandkuhler J Characterization of long-term potentiation of C-fiber-evoked potentials in spinal dorsal horn of adult rat: essential role of NK1 and NK2 receptorsJ Neurophysiol1997 7819731982

    Not in our library10.1152/jn.1997.78.4.1973

  135. 135.

    Zhang HM Zhou LJ Hu XD Hu NW Zhang T Liu XG Acute nerve injury induces long-term potentiation of C-fiber evoked field potentials in spinal dorsal horn of intact ratSheng Li Xue Bao2004 56591596

    Not in our library

  136. 136.

    Klein T Magerl W Hopf HC Sandkuhler J Treede RD Perceptual correlates of nociceptive long-term potentiation and long-term depression in humansJ Neurosci2004 24964971

    Not in our library10.1523/jneurosci.1222-03.2004

  137. 137.

    Klein T Magerl W Treede RD Perceptual correlate of nociceptive long-term potentiation (LTP) in humans shares the time course of early-LTPJ Neurophysiol2006 9635513555

    Not in our library10.1152/jn.00755.2006

  138. 138.

    Beattie EC Stellwagen D Morishita W Bresnahan JC Ha BK Von Zastrow M Beattie MS Malenka RC Control of synaptic strength by glial TNFalphaScience2002 29522822285

    Not in our library10.1126/science.1067859

  139. 139.

    Stellwagen D Malenka RC Synaptic scaling mediated by glial TNF-alphaNature2006 44010541059

    Not in our library10.1038/nature04671

  140. 140.

    Pickering M Cumiskey D O'Connor JJ Actions of TNF-alpha on glutamatergic synaptic transmission in the central nervous systemExp Physiol2005 90663670

    Not in our library10.1113/expphysiol.2005.030734

  141. 141.

    Tancredi V D'Arcangelo G Grassi F Tarroni P Palmieri G Santoni A Eusebi F Tumor necrosis factor alters synaptic transmission in rat hippocampal slicesNeurosci Lett1992 146176178

    Not in our library10.1016/0304-3940(92)90071-e

  142. 142.

    Liu YL Zhou LJ Hu NW Xu JT Wu CY Zhang T Li YY Liu XG Tumor necrosis factor-alpha induces long-term potentiation of C-fiber evoked field potentials in spinal dorsal horn in rats with nerve injury: the role of NF-kappa B, JNK and p38 MAPKNeuropharmacology2007 52708715

    Not in our library10.1016/j.neuropharm.2006.09.011

  143. 143.

    Holton FA Holton P The capillary dilator substances in dry powders of spinal roots; a possible role of adenosine triphosphate in chemical transmission from nerve endingsJ Physiol1954 126124140

    Not in our library10.1113/jphysiol.1954.sp005198

  144. 144.

    Holton P The liberation of adenosine triphosphate on antidromic stimulation of sensory nervesJ Physiol1959 145494504

    Not in our library10.1113/jphysiol.1959.sp006157

  145. 145.

    Bleehen T Keele CA Observations on the algogenic actions of adenosine compounds on the human blister base preparationPain1977 3367377

    Not in our library10.1016/0304-3959(77)90066-5

  146. 146.

    Bleehen T The effects of adenine nucleotides on cutaneous afferent nerve activityBr J Pharmacol1978 62573577

    Not in our library10.1111/j.1476-5381.1978.tb07764.x

  147. 147.

    Jahr CE Jessell TM ATP excites a subpopulation of rat dorsal horn neuronesNature1983 304730733

    Not in our library10.1038/304730a0

  148. 148.

    Burnstock G Purinergic nerves and receptorsProg Biochem Pharmacol1980 16141154

    Not in our library

  149. 149.

    Burnstock G Kennedy C Is there a basis for distinguishing two types of P2-purinoceptor?Gen Pharmacol1985 16433440

    Not in our library10.1016/0306-3623(85)90001-1

  150. 150.

    Burnstock G Purinergic signalling and disorders of the central nervous systemNat Rev Drug Discov2008 7575590

    Not in our library10.1038/nrd2605

  151. 151.

    Burnstock G Physiology and pathophysiology of purinergic neurotransmissionPhysiol Rev2007 87659797

    Not in our library10.1152/physrev.00043.2006

  152. 152.

    Amaya F Wang H Costigan M Allchorne AJ Hatcher JP Egerton J Stean T Morisset V Grose D Gunthorpe MJ The voltage-gated sodium channel Na(v)1.9 is an effector of peripheral inflammatory pain hypersensitivityJ Neurosci2006 261285212860

    Not in our library10.1523/jneurosci.4015-06.2006

  153. 153.

    Novakovic SD Kassotakis LC Oglesby IB Smith JA Eglen RM Ford AP Hunter JC Immunocytochemical localization of P2X3 purinoceptors in sensory neurons in naive rats and following neuropathic injuryPain1999 80273282

    Not in our library10.1016/s0304-3959(98)00225-5

  154. 154.

    Bradbury EJ Burnstock G McMahon SB The expression of P2X3 purinoreceptors in sensory neurons: effects of axotomy and glial-derived neurotrophic factorMol Cell Neurosci1998 12256268

    Not in our library10.1006/mcne.1998.0719

  155. 155.

    Barclay J Patel S Dorn G Wotherspoon G Moffatt S Eunson L Abdel'al S Natt F Hall J Winter J Functional downregulation of P2X3 receptor subunit in rat sensory neurons reveals a significant role in chronic neuropathic and inflammatory painJ Neurosci2002 2281398147

    Not in our library10.1523/jneurosci.22-18-08139.2002

  156. 156.

    Dorn G Patel S Wotherspoon G Hemmings-Mieszczak M Barclay J Natt FJ Martin P Bevan S Fox A Ganju P siRNA relieves chronic neuropathic painNucleic Acids Res2004 32e49

    Not in our library10.1093/nar/gnh044

  157. 157.

    Honore P Kage K Mikusa J Watt AT Johnston JF Wyatt JR Faltynek CR Jarvis MF Lynch K Analgesic profile of intrathecal P2X(3) antisense oligonucleotide treatment in chronic inflammatory and neuropathic pain states in ratsPain2002 991119

    Not in our library10.1016/s0304-3959(02)00032-5

  158. 158.

    Tsuda M Shigemoto-Mogami Y Koizumi S Mizokoshi A Kohsaka S Salter MW Inoue K P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injuryNature2003 424778783

    Not in our library10.1038/nature01786

  159. 159.

    Ulmann L Hatcher JP Hughes JP Chaumont S Green PJ Conquet F Buell GN Reeve AJ Chessell IP Rassendren F Up-regulation of P2X4 receptors in spinal microglia after peripheral nerve injury mediates BDNF release and neuropathic painJ Neurosci2008 281126311268

    Not in our library10.1523/jneurosci.2308-08.2008

  160. 160.

    Trang T Beggs S Salter MW Purinoceptors in microglia and neuropathic painPflugers Arch2006 452645652

    Not in our library10.1007/s00424-006-0074-5

  161. 161.

    Gong QJ Li YY Xin WJ Zang Y Ren WJ Wei XH Zhang T Liu XG ATP induces long-term potentiation of C-fiber-evoked field potentials in spinal dorsal horn: the roles of P2X4 receptors and p38 MAPK in microgliaGlia2009 57583591

    Not in our library10.1002/glia.20786

  162. 162.

    Suzuki T Hide I Ido K Kohsaka S Inoue K Nakata Y Production and release of neuroprotective tumor necrosis factor by P2X7 receptor-activated microgliaJ Neurosci2004 2417

    Not in our library10.1523/jneurosci.3792-03.2004

  163. 163.
    The role of the purinergic P2X7 receptor in inflammation · 2007
    No notice
  164. 164.

    Terayama R Omura S Fujisawa N Yamaai T Ichikawa H Sugimoto T Activation of microglia and p38 mitogen-activated protein kinase in the dorsal column nucleus contributes to tactile allodynia following peripheral nerve injuryNeuroscience2008 15312451255

    Not in our library10.1016/j.neuroscience.2008.03.041

  165. 165.

    Wen YR Suter MR Ji RR Yeh GC Wu YS Wang KC Kohno T Sun WZ Wang CC Activation of p38 mitogen-activated protein kinase in spinal microglia contributes to incision-induced mechanical allodyniaAnesthesiology2009 110155165

    Not in our library10.1097/aln.0b013e318190bc16

  166. 166.

    Crown ED Ye Z Johnson KM Xu GY McAdoo DJ Hulsebosch CE Increases in the activated forms of ERK 1/2, p38 MAPK, and CREB are correlated with the expression of at-level mechanical allodynia following spinal cord injuryExp Neurol2006 199397407

    Not in our library10.1016/j.expneurol.2006.01.003

  167. 167.

    Crown ED Gwak YS Ye Z Johnson KM Hulsebosch CE Activation of p38 MAP kinase is involved in central neuropathic pain following spinal cord injuryExp Neurol2008 213257267

    Not in our library10.1016/j.expneurol.2008.05.025

  168. 168.

    Schafers M Svensson CI Sommer C Sorkin LS Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neuronsJ Neurosci2003 2325172521

    Not in our library10.1523/jneurosci.23-07-02517.2003

  169. 169.

    Sun M Fink PJ A new class of reverse signaling costimulators belongs to the TNF familyJ Immunol2007 17943074312

    Not in our library10.4049/jimmunol.179.7.4307

  170. 170.

    Hao S Mata M Glorioso JC Fink DJ Gene transfer to interfere with TNFalpha signaling in neuropathic painGene Ther2007 1410101016

    Not in our library10.1038/sj.gt.3302950

  171. 171.

    Mata M Hao S Fink DJ Gene therapy directed at the neuroimmune component of chronic pain with particular attention to the role of TNF alphaNeurosci Lett2008 437209213

    Not in our library10.1016/j.neulet.2008.03.049

  172. 172.

    Shamji MF Chen J Friedman AH Richardson WJ Chilkoti A Setton LA Synthesis and characterization of a thermally-responsive tumor necrosis factor antagonistJ Control Release2008 129179186

    Not in our library10.1016/j.jconrel.2008.04.021

  173. 173.

    Shamji MF Jing L Chen J Hwang P Ghodsizadeh O Friedman AH Richardson WJ Setton LA Treatment of neuroinflammation by soluble tumor necrosis factor receptor Type II fused to a thermally responsive carrierJ Neurosurg Spine2008 9221228

    Not in our library10.3171/spi/2008/9/7/010

  174. 174.

    Sommer C Lindenlaub T Teuteberg P Schafers M Hartung T Toyka KV Anti-TNF-neutralizing antibodies reduce pain-related behavior in two different mouse models of painful mononeuropathyBrain Res2001 9138689

    Not in our library10.1016/s0006-8993(01)02743-3

  175. 175.

    Lindenlaub T Teuteberg P Hartung T Sommer C Effects of neutralizing antibodies to TNF-alpha on pain-related behavior and nerve regeneration in mice with chronic constriction injuryBrain Res2000 8661522

    Not in our library10.1016/s0006-8993(00)02190-9

  176. 176.

    Sommer C Schafers M Marziniak M Toyka KV Etanercept reduces hyperalgesia in experimental painful neuropathyJ Peripher Nerv Syst2001 66772

    Not in our library10.1046/j.1529-8027.2001.01010.x

  177. 177.

    Svensson CI Schafers M Jones TL Powell H Sorkin LS Spinal blockade of TNF blocks spinal nerve ligation-induced increases in spinal P-p38Neurosci Lett2005 379209213

    Not in our library10.1016/j.neulet.2004.12.064

  178. 178.

    Marchand F Tsantoulas C Singh D Grist J Clark AK Bradbury EJ McMahon SB Effects of Etanercept and Minocycline in a rat model of spinal cord injuryEur J Pain2009 13673681

    Not in our library10.1016/j.ejpain.2008.08.001

  179. 179.

    Si Q Nakamura Y Ogata T Kataoka K Schubert P Differential regulation of microglial activation by propentofylline via cAMP signalingBrain Res1998 81297104

    Not in our library10.1016/s0006-8993(98)00954-8

  180. 180.

    Sweitzer SM Schubert P DeLeo JA Propentofylline, a glial modulating agent, exhibits antiallodynic properties in a rat model of neuropathic painJ Pharmacol Exp Ther2001 29712101217

    Not in our library

  181. 181.

    Tawfik VL Nutile-McMenemy N Lacroix-Fralish ML Deleo JA Efficacy of propentofylline, a glial modulating agent, on existing mechanical allodynia following peripheral nerve injuryBrain Behav Immun2007 21238246

    Not in our library10.1016/j.bbi.2006.07.001

  182. 182.

    Mielke R Moller HJ Erkinjuntti T Rosenkranz B Rother M Kittner B Propentofylline in the treatment of vascular dementia and Alzheimer-type dementia: overview of phase I and phase II clinical trialsAlzheimer Dis Assoc Disord1998 12Suppl 2S2935

    Not in our library

  183. 183.

    Frampton M Harvey RJ Kirchner V Propentofylline for dementiaCochrane Database Syst Rev2003 CD002853

    Not in our library10.1002/14651858.cd002853

  184. 184.

    Bauditz J Wedel S Lochs H Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's diseaseGut2002 50196200

    Not in our library10.1136/gut.50.2.196

  185. 185.

    Moreira AL Sampaio EP Zmuidzinas A Frindt P Smith KA Kaplan G Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradationJ Exp Med1993 17716751680

    Not in our library10.1084/jem.177.6.1675

  186. 186.

    Sommer C Marziniak M Myers RR The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nervePain1998 748391

    Not in our library10.1016/s0304-3959(97)00154-1

  187. 187.

    George A Marziniak M Schafers M Toyka KV Sommer C Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-alpha, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalinPain2000 88267275

    Not in our library10.1016/s0304-3959(00)00333-x

  188. 188.

    Mackey S Feinberg S Pharmacologic therapies for complex regional pain syndromeCurr Pain Headache Rep2007 113843

    Not in our library10.1007/s11916-007-0020-z

  189. 189.

    Goli V Does thalidomide have an analgesic effect? Current status and future directionsCurr Pain Headache Rep2007 11109114

    Not in our library10.1007/s11916-007-0007-9

  190. 190.

    Clemmensen OJ Olsen PZ Andersen KE Thalidomide neurotoxicityArch Dermatol1984 120338341

    Not in our library10.1001/archderm.120.3.338

  191. 191.

    el-Badawi MG Fatani JA Bahakim H Abdalla MA Light and electron microscopic observations on the cerebellum of guinea pigs following low-dose methotrexateExp Mol Pathol1990 53211222

    Not in our library10.1016/0014-4800(90)90045-f

  192. 192.

    Montesinos MC Takedachi M Thompson LF Wilder TF Fernandez P Cronstein BN The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5'-nucleotidase: findings in a study of ecto-5'-nucleotidase gene-deficient miceArthritis Rheum2007 5614401445

    Not in our library10.1002/art.22643

  193. 193.

    Montesinos MC Yap JS Desai A Posadas I McCrary CT Cronstein BN Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritisArthritis Rheum2000 43656663

    Not in our library10.1002/1529-0131(200003)43:3<656::aid-anr23>3.0.co;2-h

  194. 194.

    Segal R Mozes E Yaron M Tartakovsky B The effects of methotrexate on the production and activity of interleukin-1Arthritis Rheum1989 32370377

    Not in our library10.1002/anr.1780320403

  195. 195.

    Hashizume H Rutkowski MD Weinstein JN DeLeo JA Central administration of methotrexate reduces mechanical allodynia in an animal model of radiculopathy/sciaticaPain2000 87159169

    Not in our library10.1016/s0304-3959(00)00281-5

  196. 196.

    Bruce-Gregorios JH Soucy D Chen MG Benson N Effect of methotrexate on cell cycle and DNA synthesis of astrocytes in primary culture: flow cytometric studiesJ Neuropathol Exp Neurol1991 506372

    Not in our library10.1097/00005072-199101000-00005

  197. 197.

    Bruce-Gregorios JH Soucy DM Chen MG Norenberg MD Effect of methotrexate on glial fibrillary acidic protein content of astrocytes in primary cultureJ Neuropathol Exp Neurol1991 50118125

    Not in our library10.1097/00005072-199103000-00003

  198. 198.

    Gregorios JB Gregorios AB Mora J Marcillo A Fojaco RM Green B Morphologic alterations in rat brain following systemic and intraventricular methotrexate injection: light and electron microscopic studiesJ Neuropathol Exp Neurol1989 483347

    Not in our library10.1097/00005072-198901000-00004

  199. 199.

    Genevay S Finckh A Payer M Mezin F Tessitore E Gabay C Guerne PA Elevated levels of tumor necrosis factor-alpha in periradicular fat tissue in patients with radiculopathy from herniated discSpine2008 3320412046

    Not in our library10.1097/brs.0b013e318183bb86

  200. 200.

    Genevay S Stingelin S Gabay C Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot studyAnn Rheum Dis2004 6311201123

    Not in our library10.1136/ard.2003.016451

  201. 201.

    Karppinen J Korhonen T Malmivaara A Paimela L Kyllonen E Lindgren KA Rantanen P Tervonen O Niinimaki J Seitsalo S Hurri H Tumor necrosis factor-alpha monoclonal antibody, infliximab, used to manage severe sciaticaSpine2003 28750753discussion 753-754

    Not in our library10.1097/00007632-200304150-00004

  202. 202.

    Korhonen T Karppinen J Malmivaara A Autio R Niinimaki J Paimela L Kyllonen E Lindgren KA Tervonen O Seitsalo S Hurri H Efficacy of infliximab for disc herniation-induced sciatica: one-year follow-upSpine2004 2921152119

    Not in our library10.1097/01.brs.0000141179.58778.6c

  203. 203.

    Korhonen T Karppinen J Paimela L Malmivaara A Lindgren KA Jarvinen S Niinimaki J Veeger N Seitsalo S Hurri H The treatment of disc herniation-induced sciatica with infliximab: results of a randomized, controlled, 3-month follow-up studySpine2005 3027242728

    Not in our library10.1097/01.brs.0000190815.13764.64

  204. 204.

    Korhonen T Karppinen J Paimela L Malmivaara A Lindgren KA Bowman C Hammond A Kirkham B Jarvinen S Niinimaki J The treatment of disc-herniation-induced sciatica with infliximab: one-year follow-up results of FIRST II, a randomized controlled trialSpine2006 3127592766

    Not in our library10.1097/01.brs.0000245873.23876.1e

  205. 205.

    Cohen SP Wenzell D Hurley RW Kurihara C Buckenmaier CC Griffith S Larkin TM Dahl E Morlando BJ A double-blind, placebo-controlled, dose-response pilot study evaluating intradiscal etanercept in patients with chronic discogenic low back pain or lumbosacral radiculopathyAnesthesiology2007 10799105

    Not in our library10.1097/01.anes.0000267518.20363.0d

  206. 206.

    Cohen SP Bogduk N Dragovich A Buckenmaier CC Griffith S Kurihara C Raymond J Richter PJ Williams N Yaksh TL Randomized, double-blind, placebo-controlled, dose-response, and preclinical safety study of transforaminal epidural etanercept for the treatment of sciaticaAnesthesiology2009 11011161126

    Not in our library10.1097/aln.0b013e3181a05aa0

  207. 207.

    Rolan P Gibbons JA He L Chang E Jones D Gross MI Davidson JB Sanftner LM Johnson KW Ibudilast in healthy volunteers: safety, tolerability and pharmacokinetics with single and multiple dosesBr J Clin Pharmacol2008 66792801

    Not in our library10.1111/j.1365-2125.2008.03270.x

  208. 208.

    Ledeboer A Liu T Shumilla JA Mahoney JH Vijay S Gross MI Vargas JA Sultzbaugh L Claypool MD Sanftner LM The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic painNeuron Glia Biol2006 2279291

    Not in our library10.1017/s1740925x0700035x

  209. 209.

    Watkins LR Milligan ED Maier SF Glial proinflammatory cytokines mediate exaggerated pain states: implications for clinical painAdv Exp Med Biol2003 521121

    Not in our library

  210. 210.

    Wieseler-Frank J Maier SF Watkins LR Glial activation and pathological painNeurochem Int2004 45389395

    Not in our library10.1016/j.neuint.2003.09.009

  211. 211.

    Milligan ED Watkins LR Pathological and protective roles of glia in chronic painNat Rev Neurosci2009 102336

    Not in our library10.1038/nrn2533

  212. 212.

    Milligan ED Sloane EM Watkins LR Glia in pathological pain: a role for fractalkineJ Neuroimmunol2008 198113120

    Not in our library10.1016/j.jneuroim.2008.04.011

  213. 213.

    Bettoni I Comelli F Rossini C Granucci F Giagnoni G Peri F Costa B Glial TLR4 receptor as new target to treat neuropathic pain: efficacy of a new receptor antagonist in a model of peripheral nerve injury in miceGlia2008 5613121319

    Not in our library10.1002/glia.20699

  214. 214.

    Schafers M Sommer C Anticytokine therapy in neuropathic pain managementExpert Rev Neurother2007 716131627

    Not in our library10.1586/14737175.7.11.1613

  215. 215.

    Gao YJ Ji RR Chemokines, neuronal-glial interactions, and central processing of neuropathic painPharmacol Ther2010 12615668

    Not in our library10.1016/j.pharmthera.2010.01.002

  216. 216.

    Ji RR Gereau RWt Malcangio M Strichartz GR MAP kinase and painBrain Res Rev2008 60113548

    Not in our library10.1016/j.brainresrev.2008.12.011

  217. 217.

    Ledeboer A Hutchinson MR Watkins LR Johnson KW Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromesExpert Opin Investig Drugs2007 16935950

    Not in our library10.1517/13543784.16.7.935

Cited by papers we hold 6

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.